Universität zu Köln

Journal Article

Horn, Leora, Rizvi, Naiyer, Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalman, Gerard, Wolf, Juergen, Paik, Paul, Zhu, Jin, Xu, Dong, Neely, Jaclyn, Qi, Zenhao, Harbison, Christopher T., Lynch, Mark and Ramalingam, Suresh S. (2015). LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC). Asia-Pac. J. Clin. Oncol., 11. S. 124 - 125. HOBOKEN: WILEY-BLACKWELL. ISSN 1743-7563

Horn, Leora, Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Paik, Paul, Li, Ang, Xu, Dong, Neely, Jaclyn, Qi, Zhenhao, Harbison, Christopher, Lynch, Mark and Ramalingam, Suresh S. (2015). Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. J. Thorac. Oncol., 10 (9). S. S175 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Horn, Leora, Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M. ORCID: 0000-0001-7041-6368, Harbison, Christopher T., Baudelet, Christine, Lestini, Brian J. and Ramalingam, Suresh S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol., 16 (3). S. 257 - 266. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Horn, Leora, Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M. ORCID: 0000-0001-7041-6368, Harbison, Christopher T., Baudelet, Christine, Lestini, Brian J. and Ramalingam, Suresh S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol., 16 (3). S. 257 - 266. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488